Advertisement
News
Subscribe to MDT Magazine News

FDA Approves New Indication for Afinitor

November 1, 2010 11:35 am | by Bio-Medicine.Org | Comments

SILVER SPRING, Md., Nov. 1, 2010 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration approved the cancer drug Afinitor (everolimus) on Friday to treat patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS), a rare genetic disorder....

TOPICS:

AACR to Host Annual Cancer Prevention Conference

November 1, 2010 11:35 am | by AACR | Comments

PHILADELPHIA - The American Association for Cancer Research will host its Ninth Annual Frontiers in Cancer Prevention Research Conference Nov. 7-10 at the Pennsylvania Convention Center in Philadelphia.

TOPICS:

Cancer Prevention Conference Underscores Need for Congress to Pass Appropriations Bill That Funds NIH

November 1, 2010 11:35 am | by AACR | Comments

PHILADELPHIA - Despite innovative cancer research being presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, as well as numerous other conferences organized by the American Association for Cancer Research each year, the pace of scientific discovery in...

TOPICS:
Advertisement

AACR Conference to Focus on Prevention, Management of Cancer in Women

November 1, 2010 11:35 am | by AACR | Comments

PHILADELPHIA - The American Association for Cancer Research will host a media forum focusing on new advancements in the prevention and patient management of cancer among women. This forum will be held here as part of the AACR's Ninth Annual Frontiers in Cancer Prevention Research...

TOPICS:

Summary Box: Humana's 3Q profit rises 30 percent

November 1, 2010 10:45 am | by The Associated Press | Comments

THE RESULTS: Managed care company Humana Inc. said Monday its third-quarter profit climbed 30 percent to $393.2 million, or $2.32 per share. Revenue rose 9 percent to $8.42 billion.THE REASONS: The Louisville, Ky., insurer said Medicare Advantage enrollment climbed 17 percent in the quarter and...

Hologic Announces Long-term, Five-year Results from MammoSite® ASBS Registry Study

November 1, 2010 6:35 am | by Bio-Medicine.Org | Comments

BEDFORD, Mass., Nov. 1, 2010 /- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX ), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the...

TOPICS:

Philips Showcases Integrated Radiation Oncology Suite to Simplify Treatment Planning

November 1, 2010 6:35 am | by Bio-Medicine.Org | Comments

SAN DIEGO, Nov. 1, 2010 /- At this year's Annual Meeting of the American Society for Radiation Oncology (ASTRO), Royal Philips Electronics (NYSE: PHG, AEX: PHI) is demonstrating how the integration of imaging and treatment planning can help simplify the clinician and patient experience....

TOPICS:

Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010

November 1, 2010 6:33 am | by Bio-Medicine.Org | Comments

MOUNTAIN VIEW, Calif., Nov. 1, 2010 /- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it will report results for its fiscal quarter ended September 30, 2010, on Tuesday, November 9, 2010 following the close of the U.S. financial markets.  As the Company recently...

TOPICS:
Advertisement

Veroâ„¢ SBRT Unleashed

November 1, 2010 6:33 am | by Bio-Medicine.Org | Comments

SAN DIEGO, Nov. 1 /- ASTRO, the annual meeting of the American Society for Therapeutic Radiology and Oncology, marks the introduction of Vero™ SBRT to the broader North American audience. The Vero SBRT system offers the latest in radiation technology: dynamic tumor tracking and...

TOPICS:

AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTAâ„¢ on Monday November 1, 2010

November 1, 2010 3:34 am | by Bio-Medicine.Org | Comments

ALISO VIEJO, Calif., Nov. 1, 2010 /- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR ) today announced a management conference call to discuss the approval of NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) by the U.S. Food and Drug Administration (FDA).  The call is...

TOPICS:

LitePoint Joins Continua Health Alliance

November 1, 2010 3:33 am | by Bio-Medicine.Org | Comments

SUNNYVALE, Calif., Nov. 1, 2010 /- LitePoint Corporation, the leader in wireless test solutions, announced today it has joined Continua Health Alliance, along with other technology leaders. The alliance's mission is to improve the quality of personal healthcare and to establish a system...

TOPICS:

7,000 Bracelets For Hopeâ„¢ - A Rare Disease Awareness Campaign

November 1, 2010 3:33 am | by Bio-Medicine.Org | Comments

DANA POINT, Calif., Nov. 1, 2010 /PRNewswire-USNewswire/ -- The Global Genes Project ( www.globalgenesproject.org ), a non-profit advocacy organization that aims to raise awareness about the prevalence of rare diseases worldwide, today launched the 7,000 Bracelets for Hope™...

TOPICS:

Humana's 3rd-quarter earnings rise 30 percent

November 1, 2010 2:45 am | by The Associated Press | Comments

Humana Inc.'s third-quarter net income climbed 30 percent partly on higher than expected medicals claims as Medicare Advantage enrollment rose.The health insurer also boosted its full-year earnings guidance on Monday.Humana is the second largest provider of Medicare Advantage plans, trailing...

Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD

November 1, 2010 1:34 am | by Bio-Medicine.Org | Comments

Medivir Notes That Partner Tibotec Announced Week 24 Interim Results Fro...

TOPICS:

Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®

November 1, 2010 1:34 am | by Bio-Medicine.Org | Comments

SEATTLE, Nov. 1, 2010 /- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it has submitted a Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA") for Pixuvri® (pixantrone dimaleate) as monotherapy for the treatment of adult...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading